​

Ligand Pharmaceuticals (LGND) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Ligand Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$167.13M

Latest Revenue (Q)

$51.81M

Main Segment (Y)

Royalty

Ligand Pharmaceuticals Revenue by Period

Ligand Pharmaceuticals Revenue by Year

DateRevenueChange
2024-12-31$167.13M27.28%
2023-12-31$131.31M-33.09%
2022-12-31$196.25M-29.19%
2021-12-31$277.13M48.66%
2020-12-31$186.42M54.98%
2019-12-31$120.28M-52.17%
2018-12-31$251.45M78.21%
2017-12-31$141.10M29.48%
2016-12-31$108.97M51.53%
2015-12-31$71.91M11.43%
2014-12-31$64.54M31.78%
2013-12-31$48.97M56.03%
2012-12-31$31.39M4.50%
2011-12-31$30.04M27.61%
2010-12-31$23.54M-39.55%
2009-12-31$38.94M42.56%
2008-12-31$27.32M111.84%
2007-12-31$12.89M-90.85%
2006-12-31$140.96M-20.18%
2005-12-31$176.61M8.01%
2004-12-31$163.51M15.85%
2003-12-31$141.14M46.05%
2002-12-31$96.64M26.59%
2001-12-31$76.34M58.68%
2000-12-31$48.11M17.63%
1999-12-31$40.90M131.07%
1998-12-31$17.70M-65.76%
1997-12-31$51.70M40.49%
1996-12-31$36.80M50.20%
1995-12-31$24.50M84.21%
1994-12-31$13.30M-

Ligand Pharmaceuticals generated $167.13M in revenue during NA 2024, up 27.28% compared to the previous quarter, and up 138.95% compared to the same period a year ago.

Ligand Pharmaceuticals Revenue by Quarter

DateRevenueChange
2024-09-30$51.81M24.76%
2024-06-30$41.53M34.07%
2024-03-31$30.98M10.24%
2023-12-31$28.10M-14.50%
2023-09-30$32.87M24.66%
2023-06-30$26.37M-40.05%
2023-03-31$43.98M-12.71%
2022-12-31$50.38M-23.77%
2022-09-30$66.09M15.10%
2022-06-30$57.42M25.66%
2022-03-31$45.69M-36.95%
2021-12-31$72.47M11.78%
2021-09-30$64.83M-23.43%
2021-06-30$84.67M53.54%
2021-03-31$55.15M-21.20%
2020-12-31$69.99M67.25%
2020-09-30$41.85M1.03%
2020-06-30$41.42M24.91%
2020-03-31$33.16M22.80%
2019-12-31$27.00M8.85%
2019-09-30$24.81M-0.72%
2019-06-30$24.99M-42.54%
2019-03-31$43.48M-27.03%
2018-12-31$59.59M30.50%
2018-09-30$45.66M-49.29%
2018-06-30$90.04M60.34%
2018-03-31$56.16M11.28%
2017-12-31$50.46M51.20%
2017-09-30$33.38M19.22%
2017-06-30$28.00M-4.35%
2017-03-31$29.27M-23.35%
2016-12-31$38.19M76.63%
2016-09-30$21.62M10.75%
2016-06-30$19.52M-34.16%
2016-03-31$29.65M39.90%
2015-12-31$21.19M19.72%
2015-09-30$17.70M-3.89%
2015-06-30$18.42M26.13%
2015-03-31$14.60M-36.51%
2014-12-31$23.00M53.60%
2014-09-30$14.97M41.15%
2014-06-30$10.61M-33.53%
2014-03-31$15.96M8.29%
2013-12-31$14.74M13.32%
2013-09-30$13.01M35.75%
2013-06-30$9.58M-17.78%
2013-03-31$11.65M-14.55%
2012-12-31$13.63M113.88%
2012-09-30$6.38M11.02%
2012-06-30$5.74M1.88%
2012-03-31$5.64M-56.43%
2011-12-31$12.94M125.33%
2011-09-30$5.74M-23.07%
2011-06-30$7.46M91.56%
2011-03-31$3.90M-1.12%
2010-12-31$3.94M-49.50%
2010-09-30$7.80M33.64%
2010-06-30$5.84M-2.01%
2010-03-31$5.96M-57.37%
2009-12-31$13.98M76.90%
2009-09-30$7.90M4.04%
2009-06-30$7.59M-19.81%
2009-03-31$9.47M-23.56%
2008-12-31$12.39M136.07%
2008-09-30$5.25M9.24%
2008-06-30$4.80M-1.44%
2008-03-31$4.87M-15.53%
2007-12-31$5.77M-

Ligand Pharmaceuticals generated $51.81M in revenue during Q3 2024, up 24.76% compared to the previous quarter, and up 196.51% compared to the same period a year ago.

Ligand Pharmaceuticals Revenue Breakdown

Ligand Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24Dec 22Dec 21Dec 20Dec 19
Contract Revenue$27.48M$19.22M$63.96M$42.66M-
Financial Royalty Assets$13.44M----
Intangible Royalty Assets$95.33M----
License Fees$1.94M$2.85M$5.08M$4.38M$6.20M
Material Sales, Captisol$30.88M$104.50M$164.25M$109.96M$31.49M
Material Sales, Captisol, Core$30.88M$16.43M---
Royalty$108.77M$72.53M$48.93M$46.98M-
Royalty, Evomela$8.68M$10.20M$10.08M$5.17M-
Royalty, Kyprolis$38.38M$30.12M$27.47M$25.05M-
Royalty, Other$8.95M$7.63M$11.38M$2.57M-
Service$25.53M$1.12M$23.71M$21.80M-
Milestone-$9.15M$28.75M$11.52M$23.45M
Material Sales, Captisol, COVID-$88.07M---
License Fees, Milestones, and Other Product, Other-$6.11M$6.41M$4.97M$12.17M
License Fees, Milestones, and Product, Other----$41.82M
Royalty, Promacta----$14.19M

Ligand Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 24: Royalty (27.87%), Intangible Royalty Assets (24.43%), Royalty, Kyprolis (9.83%), Material Sales, Captisol (7.91%), Material Sales, Captisol, Core (7.91%), Contract Revenue (7.04%), Service (6.54%), Financial Royalty Assets (3.44%), Royalty, Other (2.29%), Royalty, Evomela (2.22%), and License Fees (0.50%).

Quarterly Revenue by Product

Product/ServiceDec 24Sep 24Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Sep 21Jun 21Mar 21Sep 20Jun 20Mar 20Sep 19Jun 19Mar 19Sep 18Jun 18Mar 18
Royalty$77.06M$31.71M$20.43M$17.15M$21.04M$19.84M$17.96M$13.70M$15.65M$8.62M$7.11M$9.01M$7.18M$6.57M$20.80M-----
Royalty, Other$6.67M$2.27M$3.33M$2.27M$3.78M$1.42M$619.00K$1.81M$4.16M$983.00K$492.00K$280.00K$501.00K$584.00K------
Material Sales, Captisol$24.63M$6.25M$5.22M$10.62M$26.88M$35.95M$29.55M$12.12M$35.09M$62.51M$31.27M$23.39M$7.61M$4.39M------
Financial Royalty Assets$8.29M$5.16M------------------
Intangible Royalty Assets$68.78M$26.55M------------------
Rylaze-$3.89M$3.03M$2.61M$2.10M$2.32M$1.65M-------------
Kyprolis-$11.60M$8.10M$6.23M$9.12M$7.13M$4.62M$8.82M$5.44M$4.29M$6.92M$5.48M$4.41M-------
Teriparatide Injection-$2.38M$3.61M$3.50M$4.07M$5.50M$2.91M-------------
Evomela-$1.75M$2.36M$2.55M$3.12M$2.39M$2.70M$2.67M$2.19M$2.33M$1.80M$1.20M$1.58M-------
Material Sales, Captisol, Core--$5.22M$10.62M$3.30M$3.58M$3.33M$6.23M------------
Milestone---$15.30M$-4.87M$3.66M$1.27M$9.09M$7.42M$3.60M$8.42M$960.00K$1.92M$2.83M------
Contract Revenue--$716.00K$16.20M$-20.87M$10.30M$9.91M$19.88M$14.09M$13.55M$16.77M$9.45M$5.19M$2.13M------
License Fees--$508.00K$114.00K$-2.31M$460.00K$1.61M$3.09M$200.00K$1.05M$1.04M$158.00K$47.98M$26.95M------
License Fees, Milestones, and Product, Other, Product, Other--$208.00K$789.00K$1.21M$1.58M$2.56M$1.65M$1.54M$1.84M$995.00K$1.14M$1.17M-------
Material Sales, Captisol, COVID----$23.58M$32.37M$26.22M$5.90M------------
Contract Revenue, Service-----$4.97M$5.45M$5.15M$4.83M$7.36M$5.46M$7.34M--------
Promacta----------------$14.19M---
Service------------$4.58M$3.36M------
MilestoneMember------------$3.47M$334.00K------
MaterialSalesCaptisolMember------------$24.47M$21.11M$7.03M-----
LicenseFeesMilestonesandProductOtherProductOtherMember------------$1.06M$821.00K------
LicenseFeesMember------------$660.00K$975.00K------
LicenseFeesMilestonesandProductOtherMember-----------------$2.51M--
License Fees, Milestones, and Product, Other------------------$51.03M$30.95M
Royalty, Evomela-------------------$1.60M
Royalty, Kyprolis-------------------$3.30M
Royalty, Product, Other-------------------$400.00K
Royalty, Promacta-------------------$15.60M

Ligand Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Royalty (41.56%), Intangible Royalty Assets (37.09%), Material Sales, Captisol (13.28%), Financial Royalty Assets (4.47%), and Royalty, Other (3.60%).

Ligand Pharmaceuticals Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
BGNEBeiGene$2.46B$929.17M
APLSApellis Pharmaceuticals$709.95M$176.57M
BPMCBlueprint Medicines$508.82M$128.18M
ASNDAscendis Pharma$266.72M$95.89M
RCUSArcus Biosciences$258.00M$48.00M
LGNDLigand Pharmaceuticals$167.13M$51.81M
CYTKCytokinetics$18.47M$463.00K
RLAYRelay Therapeutics$10.01M-
CRNXCrinetics Pharmaceuticals$1.04M-
DSGNDesign Therapeutics--
CGEMCullinan Oncology--
GPCRStructure Therapeutics--
ETNB89bio--
AKROAkero Therapeutics--
VRDNViridian Therapeutics-$86.00K
ANNXAnnexon--
TERNTerns Pharmaceuticals--
PASGPassage Bio--
LYELLyell Immunopharma-$34.00K
ORICORIC Pharmaceuticals--

LGND Revenue FAQ

What is Ligand Pharmaceuticals’s yearly revenue?

Ligand Pharmaceuticals's yearly revenue for 2024 was $167.13M, representing an increase of 27.28% compared to 2023. The company's yearly revenue for 2023 was $131.31M, representing a decrease of -33.09% compared to 2022. LGND's yearly revenue for 2022 was $196.24M, representing a decrease of -29.19% compared to 2021.

What is Ligand Pharmaceuticals’s quarterly revenue?

Ligand Pharmaceuticals's quarterly revenue for Q3 2024 was $51.81M, a 24.76% increase from the previous quarter (Q2 2024), and a 57.64% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $41.53M, a 34.07% increase from the previous quarter (Q1 2024), and a 57.52% increase year-over-year (Q2 2023). LGND's quarterly revenue for Q1 2024 was $30.98M, a 10.24% increase from the previous quarter (Q4 2023), and a -29.56% decrease year-over-year (Q1 2023).

What is Ligand Pharmaceuticals’s revenue growth rate?

Ligand Pharmaceuticals's revenue growth rate for the last 3 years (2022-2024) was -14.83%, and for the last 5 years (2020-2024) was -10.35%.

What are Ligand Pharmaceuticals’s revenue streams?

Ligand Pharmaceuticals's revenue streams in c 24 are Contract Revenue, Financial Royalty Assets, Intangible Royalty Assets, License Fees, Material Sales, Captisol, Material Sales, Captisol, Core, Royalty, Royalty, Evomela, Royalty, Kyprolis, Royalty, Other, and Service. Contract Revenue generated $27.48M in revenue, accounting 7.04% of the company's total revenue, up 42.94% year-over-year. Financial Royalty Assets generated $13.44M in revenue, accounting 3.44% of the company's total revenue Intangible Royalty Assets generated $95.33M in revenue, accounting 24.43% of the company's total revenue License Fees generated $1.94M in revenue, accounting 0.50% of the company's total revenue, down -31.77% year-over-year. Material Sales, Captisol generated $30.88M in revenue, accounting 7.91% of the company's total revenue, down -70.45% year-over-year. Material Sales, Captisol, Core generated $30.88M in revenue, accounting 7.91% of the company's total revenue, up 87.98% year-over-year. Royalty generated $108.77M in revenue, accounting 27.87% of the company's total revenue, up 49.98% year-over-year. Royalty, Evomela generated $8.68M in revenue, accounting 2.22% of the company's total revenue, down -14.88% year-over-year. Royalty, Kyprolis generated $38.38M in revenue, accounting 9.83% of the company's total revenue, up 27.43% year-over-year. Royalty, Other generated $8.94M in revenue, accounting 2.29% of the company's total revenue, up 17.19% year-over-year. Service generated $25.53M in revenue, accounting 6.54% of the company's total revenue, up 2185.85% year-over-year.

What is Ligand Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Ligand Pharmaceuticals was Royalty. This segment made a revenue of $108.77M, representing 27.87% of the company's total revenue.